Genomic analyses (whole-genome sequencing, rearrangement mapping, and exome sequencing) identified ARID1A/ARID1B deletions or mutations in 8/71 pediatric NB cases, which correlated with early treatment failure and poorer survival (11). This evidence concerns the gene ARID1B and neuroblastoma.